Quick Answer
Bolt Biotherapeutics, Inc. reported Diluted EPS of $17.85 per share (loss) for fiscal year 2025.
Bolt Biotherapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$17.85 | +46.0% |
| 2024 | -$33.06 | -1706.6% |
| 2023 | -$1.83 | +22.5% |
| 2022 | -$2.36 | +20.5% |
| 2021 | -$2.97 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$3.72 | +53.1% | +16.6% |
| June 30, 2025 | -$4.46 | +59.9% | -1437.9% |
| March 31, 2025 | -$0.29 | -3.6% | +96.3% |
| September 30, 2024 | -$7.93 | -1744.2% | +28.7% |
| June 30, 2024 | -$11.12 | -2216.7% | -3871.4% |
| March 31, 2024 | -$0.28 | +37.8% | +34.9% |
| September 30, 2023 | -$0.43 | +25.9% | +10.4% |
| June 30, 2023 | -$0.48 | +21.3% | -6.7% |
- Bolt Biotherapeutics, Inc. showed an increase of +46.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Bolt Biotherapeutics, Inc.’s diluted eps has declined by 501.0% (from $2.97 per share (loss) to $17.85 per share (loss)).
- The most recent figure is from Bolt Biotherapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: